FLORENCE, Italy, May 8 (UPI) — Depot medroxyprogesterone acetate, a commonly used injectable contraceptive, is linked to a higher risk of bone fracture, U.S. and Swiss researchers say.
Researchers at the University Hospital Basel in Switzerland and the Boston University Medical Center said DMPA — a progestin-only long acting reversible hormonal birth control drug which is injected every 3 months — is associated with higher bone fracture risk when used alone and not in combination with estrogen.
The researchers analyzed the relationship between long-term use of DMPA — with or without estrogen — and the risk of fractures.
The study found for women age 50 and younger, the use of DMPA for two or more years is associated with a 50 percent increased risk of fracture, but for those using the combined estrogen-containing oral contraceptives the risk of fracture was not increased.
The study was presented at the World Congress on Osteoporosis in Florence, Italy.
Copyright 2010 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI’s prior written consent.